{"id":4462,"date":"2026-03-12T15:55:06","date_gmt":"2026-03-12T15:55:06","guid":{"rendered":"https:\/\/inimmune.com\/?p=4462"},"modified":"2026-06-01T12:38:16","modified_gmt":"2026-06-01T12:38:16","slug":"inimmune-completes-enrollment-and-doses-first-patient-in-phase-2-chamber-trial-of-ini-2004-for-allergic-rhinitis","status":"publish","type":"post","link":"https:\/\/inimmune.com\/?p=4462","title":{"rendered":"Inimmune Completes Enrollment and Doses First Patient in Phase 2 Chamber Trial of INI-2004 for Allergic Rhinitis"},"content":{"rendered":"\n

INI-2004 advances as a rapid, disease-modifying immunotherapy for allergic rhinitis with platform potential across all allergic diseases; topline data expected June 2026<\/em><\/p>\n\n\n\n

Missoula, MT \u2014 March 11, 2026<\/em><\/strong> \u2014 Inimmune Corporation, a clinical-stage biotechnology company developing novel immunotherapies for allergic diseases, today announced the completion of enrollment and dosing of the first patient in its Phase 2 allergen challenge chamber trial evaluating INI-2004 in patients with allergic rhinitis.<\/p>\n\n\n\n

\u201cAllergic rhinitis affects hundreds of millions of people worldwide, yet treatment options remain largely limited to symptom control or lengthy allergen-specific immunotherapy programs,\u201d said David Burkhart, Ph.D., CEO of Inimmune Corporation. \u201cCompleting enrollment and dosing the first patient in our Phase 2 study is a significant step toward demonstrating that INI-2004 can rapidly and durably modify the immune response driving allergic disease. We look forward to reporting topline data from the study in June.\u201d<\/p>\n\n\n\n

The randomized, placebo-controlled Phase 2 trial is designed to evaluate the safety, tolerability, and efficacy of INI-2004 in patients with allergic rhinitis using a validated allergen exposure chamber model. INI-2004 targets innate immune pathways that drive allergic inflammation and is designed to rapidly reprogram immune responses to allergens, potentially delivering a disease-modifying effect independent of the specific allergen trigger.<\/p>\n\n\n\n

\u201cWe believe INI-2004 represents a true \u2018pipeline in a product,\u2019\u201d said Ferdinand Massari, M.D., Chief Medical Officer of Inimmune Corporation. \u201cBy targeting core innate immune pathways involved in allergic disease, this program has the potential to extend beyond seasonal and perennial allergic rhinitis into additional indications, such as food allergies, allergic asthma, and other atopic conditions. Our goal is to deliver a disease-modifying immunotherapy that simplifies treatment for patients and clinicians while transforming how allergic diseases are managed.\u201d<\/p>\n\n\n\n

Following completion of the Phase 2 allergen chamber study, Inimmune plans to engage with regulatory authorities to determine the path forward for late-stage clinical development and potential expansion into additional allergic and asthma-related indications.<\/p>\n\n\n\n

About INI-2004<\/strong><\/p>\n\n\n\n

INI-2004 is an investigational, allergen-agnostic immunotherapy designed to reprogram immune responses to allergens by activating toll-like receptor 4 (TLR4), a key pathway involved in innate immune signaling. By targeting core immune mechanisms underlying allergic disease, INI-2004 is being developed as a rapid, disease-modifying treatment that may be effective across multiple allergens.<\/p>\n\n\n\n

Inimmune is advancing INI-2004 into clinical studies designed to further evaluate its safety and efficacy in allergic rhinitis and other allergic diseases.<\/p>\n","protected":false},"excerpt":{"rendered":"

INI-2004 advances as a rapid, disease-modifying immunotherapy for allergic rhinitis with platform potential across all allergic diseases; topline data expected June 2026 Missoula, MT \u2014 March 11, 2026 \u2014 Inimmune Corporation, a clinical-stage biotechnology company developing novel immunotherapies for allergic diseases, today announced the completion of enrollment and dosing of the first patient in its […]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[29],"publication-year":[42],"class_list":["post-4462","post","type-post","status-publish","format-standard","hentry","category-press-releases","tag-featured","publication-year-42"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t